<DOC>
	<DOCNO>NCT00901069</DOCNO>
	<brief_summary>This phase I , prospective , open label , dose escalation study azacitidine combination rituximab , vincristine , cyclophosphamide treatment refractory lymphoma . The investigator expect enroll 12-24 patient trial 2 year accrual period .</brief_summary>
	<brief_title>Azacitidine With Rituximab , Vincristine , Cyclophosphamide Refractory Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patient authorize legally acceptable representative must consent study must sign date approved consent form conform federal institutional guideline . 2 . Age â‰¥ 18 year without maximum age . 3 . All patient reproductive potential plan conceive child treatment program must agree use medically accept form contraception . 4 . Women childbearing potential must negative serum pregnancy test within 2 week begin treatment . 5 . Patients must relapse lymphoma . 6 . ECOG performance status 2 well . 1 . Pregnant breastfeeding time propose study entry 2 . Clinical AIDS ARS know positive HIV serology 3 . History malignant neoplasm , lymphoma , treat within two year prior study entry ( nonmelanoma skin cancer situ cervical cancer ) current evidence recurrent metastatic disease 4 . Psychiatric additive disorder would preclude obtain informed consent 5 . Serum bilirubin &gt; 1.5 time upper limit normal range laboratory ( ULN ) . Higher level acceptable attribute active hemolysis 6 . Serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamicpyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) level &gt; 2 time ULN 7 . Serum creatinine level &gt; 1.5 time ULN 8 . Platelets &lt; 75,000/mm3 9 . Absolute neutrophil count &lt; 1500/mm3 10 . Active infection include viral hepatitis 11 . Known suspected hypersensitivity mannitol , azacitidine , rituximab 12 . Grade 3 4 neuropathy 13 . Advanced hepatic tumor 14 . Uncompensated heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>